# Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting
Canonical URL: https://biopharmsignal.com/news/CRBU/caribou-biosciences-to-highlight-vispa-cel-and-cb-011-programs-during-oral-presentations-at-the-2026-european-hematology-association-eha-annual-meeting
Ticker: CRBU
Company: Caribou
Source: Caribou
Published: 2026-05-12 13:30 EST
Original Source URL: https://investor.cariboubio.com
## Summary

BERKELEY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two abstracts have been accepted for oral presentations at the 2026 European Hematology Association (EHA) Annual

## Article Body
BERKELEY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two abstracts have been accepted for oral presentations at the 2026 European Hematology Association (EHA) Annual
## Recent Company News
- 2026-05-27 20:05 EST — [Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/CRBU/caribou-biosciences-to-participate-in-the-2026-jefferies-global-healthcare-conference) — Source: Caribou
- 2026-05-13 20:05 EST — [Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference](https://biopharmsignal.com/news/CRBU/caribou-biosciences-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference) — Source: Caribou
- 2026-05-12 13:30 EST — [Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting](https://biopharmsignal.com/news/CRBU/caribou-biosciences-to-highlight-vispa-cel-and-cb-011-programs-during-oral-presentations-at-the-2026-european-hematology-association-eha-annual-meeting) — Source: Caribou
- 2026-05-07 20:06 EST — [Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/CRBU/caribou-biosciences-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: Caribou
- 2026-05-05 20:05 EST — [Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference](https://biopharmsignal.com/news/CRBU/caribou-biosciences-to-participate-in-the-bofa-securities-2026-health-care-conference) — Source: Caribou
## Related News
- 2026-07-22 20:15 EST — BFRG — [BullFrog AI to Participate in the BTIG Virtual Biotechnology Conference](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-the-btig-virtual-biotechnology-conference-5880a10e)
- 2026-07-22 20:05 EST — AZTA — [Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast](https://biopharmsignal.com/news/AZTA/azenta-announces-fiscal-2026-third-quarter-conference-call-and-webcast-48419fff)
- 2026-07-22 20:05 EST — VKTX — [Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july--bbf2553f)
- 2026-07-22 20:01 EST — AXON — [Axon to Release Second Quarter 2026 Earnings on August 5, 2026](https://biopharmsignal.com/news/AXON/axon-to-release-second-quarter-2026-earnings-on-august-5-2026-66120902)
- 2026-07-22 12:39 EST — ARTL — [New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition](https://biopharmsignal.com/news/ARTL/new-analysis-of-over-50-studies-showed-that-all-the-non-prescription-cbd-product-a3445432)